• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog
  • News & Events
  • Videos
  • Resources
main-logo-small

Compliance Architects

Consulting Technology Outsourcing

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

FDA 483 & Warning Letter Response & Planning — DOs and DON’Ts

If you are reading this now, you are probably in the middle of an enforcement crisis.   Responding to an FDA-483, Warning Letter, or in some cases, a product seizure or injunction can be one of the most important, and most challenging, activities in your company’s history.  Failing to ensure a proper response and failing to satisfy the FDA can be fatal to your business.

FDA’s enforcement arm is back in business!  Commissioner of Food and Drugs Margaret A. Hamburg, M.D. has announced the following at an August 6, 2009 FDLI Conference in Washington DC:

  • “The FDA must be vigilant, the FDA must be strategic, the FDA must be quick, and the FDA must be visible.”
  • “We must get the word out that the FDA is on the job.”
  • “[I]n some cases, serious violations have gone unaddressed for far too long” and that enforcement action “can be too long and arduous when the public’s health is in jeopardy.”

Read the full text of the Commissioner’s speech here:  FDA Commissioner Margaret A. Hamburg, M.D. Enforcement Speech

Watch the video of the Commissioner’s speech here:

FDA Commissioner Margaret A. Hamburg, M.D. Speech Video

These statements, together with the new FDA 483/Warning Letter policy (below) add up to a new era in FDA enforcement, and one that will require the most experienced and capable team to ensure your don’t risk your business by being unprepared.

In our lengthy industry experience, your company must understand that there are absolute Dos and Don’ts in responding to the FDA:

DO:

  • Unless you are an expert in FDA 483 responses, get an expert in FDA response preparation to assist you, right away, with the response to the enforcement action!
  • Respond within 14 calendar days (10 business days) regardless of whether you are completely ready to respond or not.
    • NOTE:  As of 9/15/2009, FDA has enacted a new policy that FDA will issue automatic Warning Letters to companies that fail to respond to FDA 483s within 15 days!   This is a significant policy change, and one that is indicative of the increased enforcement posture of the FDA.
  • Strike a conciliatory and contrite tone in your communications, but, be sensitive to admissions of noncompliance
  • Offer a complete, thorough and compelling remediation plan that addresses the discrete observation, but also identifies and remediates the root cause of the deficiency.
  • At a minimum, notify FDA counsel of the situation, and preferably, ensure all communications with the FDA are reviewed by counsel.
  • Establish TRUST with the FDA.  If the FDA believes they can trust you, they will be more open to your approaches, plans, and efforts.  On the contrary, if they feel they CANNOT trust you, you may very well be targeted for further enforcement action, and your life will get VERY difficult.

Here are some thoughts from the FDA on the topic:  Responding to an FDA 483

DON’T:

  • Complain about how the FDA is picking on you.  They aren’t.   FDA is charged with protecting the public health and safety.   They have no concern whether your business makes money or not.   They aren’t bad people — in fact, they are doing a very valuable job.  Simply don’t mistake their mission or think you can persuade them that you’re being singled out or targeted unfairly.  It won’t work, and it will only serve to decrease cooperation.
  • Be late with your response.   It does not matter how busy you are — you must get the response in timely.  Although there is no regulatory limit (but see note on response timing above!) on when your responses have to be in, the Agency will perceive your lack of concern from the timeliness of your responses.
  • Challenge the FDA’s interpretation of the law or regulation unless you’ve obtained expert counsel.   In most cases it is not advisable to challenge the FDA’s interpretation of law or regulation, but certainly not without expert advice.
  • Assume that you are out of the woods because you haven’t heard back from the FDA on your response.  You should be undergoing a comprehensive compliance assessment to ensure that when they do walk back in your door — and they will — that you will present a world-class quality and compliance operation that will fully meet their expectations.

These Dos and Don’ts have been tried and tested in multiple enforcement scenarios within multiple companies.    If any of this is unfamiliar to you, CALL AN EXPERT!   Dealing with the FDA can be done predictably and cost-effectively, IF you have the right experts on your team.  Don’t make the mistake of trying to do it yourself.

For additional information, find out more at www.compliancearchitects.com

Filed Under: FDA Enforcement Tagged With: FDA 483, FDA compliance, FDA Enforcement, FDA inspections, fda quality, FDA regulatory, FDA regulatory compliance, FDA Warning Letter

Primary Sidebar

Sign Up To Our Newsletter

You May Also Like

Proud to be a Silver Sponsor of RIC’s Inaugural Annual Meeting! Join us March 22-23, 2023 at Convene in Arlington, VA!

Compliance Architects is proud to be Silver Sponsor of this year's RIC's inaugural annual meeting! The REMS Industry Consortium fosters collaboration and innovation to advance

Join the Team at Compliance Architects as our Content Marketing Manager!

This excellent opportunity will require the successful candidate to lead the technical content marketing and marketing automation activities as well as enable, manage, and drive
life sciences staffing

Talk to us about current talent trends, and what the industry will need in the next 5 to 10 years?

Transcript taken from 2022 PMWS by Executive Platforms The talent crisis as it has been called is certainly not something that has gone away or

Footer

Compliance Architects®

  • Contact Us
  • (888) 734-9778
  • info@compliancearchitects.com

Quick Links

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Our Services

  • Inspection Readiness & Enforcement
  • FDA Quality Consulting – Systems and Training
  • Quality Assurance and Engineering
  • Corporate Compliance and Litigation Services
  • FDA Regulatory Consultants – Due Diligence
  • Quality, Compliance, Regulatory & Operations’ Staffing Services

Proprietary Solutions

  • Writing for Compliance®
  • Quality Pulse®
  • CRPN Quality Roadmap®

© 2009-2023 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.

  • Debarment Certification Statement
  • Privacy Policy
  • Terms of Use

Contact Us Today

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT